Here's why Medical Developments (ASX: MVP) share price has soared 12% today

The Medical Developments share price has rocketed 11.8% today after the company announced a new executive lineup

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medical Developments International Ltd (ASX: MVP) share price has surged 11.83% to $5.86 at the time of writing, after coming out of a trading halt this morning.

Medical Developments had asked for a trading halt ahead of today's announcement of significant personnel changes. 

row of piggy banks with large one receiving injection representing rising Immutep share price

Image source: Getty Images

What did the company announce?

The company announced the appointment of Brent McGregor as the new chief executive officer. Mr McGregor previously worked for CSL Limited (ASX: CSL) subsidiary Seqirus, which was formed from CSL's acquisition of the Novartis influenza vaccine. 

Seqirus had a turnover of around $700 million and was loss-making in 2015 when Mr McGregor joined the company. By 2019, Seqirus had a turnover of $1.2 billion and EBIT of around $150 million. According to Medical Developments, Mr McGregor was central to the Seqirus globalisation and was focused on research and development, and cost management.

Previously, Mr McGregor held senior executive roles at Novartis after working in leadership roles for Sanofi Pastuer, where he had a 16-year career. Mr McGregor will take the reins as Medical Developments CEO from 1 November 2020. 

The company also appointed a new non-executive director, Gordon Naylor. Mr Naylor also previously worked for CSL, clocking up 30 years with the company. He held leadership positions including CFO and later president of Seqirus.

Medical Developments chair David Williams said the fact that Mr McGregor and Mr Naylor had previously worked closely together at Seqirus was an added benefit for the company.

About the Medical Developments share price

Medical Developments is a pharmaceutical company that specialises in emergency pain relief and asthma medication. The company has been listed on the ASX since 2003.

 In the year to 30 June 2020, Medical Developments had record revenue of $23.6 million. The company had earnings per share of .58 cents in FY2020.

The Medical Developments share price is up 51.60% since its 52-week low of $3.76. However, it is down 36.67% since the beginning of the year. The Medical Developments share price is up 16.80% since this time last year.

Chris Chitty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. and Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Ord Minnett says this ASX 200 stock can rise 40%

Big returns could be on offer with this top stock.

Read more »

comical investor reading documents and surrounded by calculators
Broker Notes

6 ASX shares at 52-week lows: Buy, hold, or sell?

The market finished lower on Thursday as the conflict in Iran dragged on.

Read more »

A girl sits on her bed in her room while using laptop and listening to headphones.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing session for the markets this Thursday.

Read more »

Man going down a red arrow, symbolising a sliding share price.
Record Lows

This ASX retail giant's shares just hit a record low. What's going on?

Ongoing margin pressure keeps Endeavour shares near record lows.

Read more »

A wine technician in overalls holds a glass of red wine up to the light and studies it.
52-Week Lows

Treasury Wine shares just tumbled to 14-year lows. Screaming bargain or falling knife?

Trading at 14-year lows, are Treasury Wine shares poised for a rebound?

Read more »

A worried woman sits at her computer with her hands clutched at the bottom of her face.
Share Fallers

These 3 ASX 200 shares have hit fresh multi-year lows: Buy, sell or hold?

One of these stocks has crashed over 50% over the past year alone.

Read more »

Business people discussing project on digital tablet.
Broker Notes

Buy, hold, sell: Breville, Collins Foods, and MA Financial shares

Let's see if analysts are bullish or bearish on these names.

Read more »

Smiling couple looking at a phone at a bargain opportunity.
Share Gainers

Why Catapult, DroneShield, Infratil, and Qoria shares are charging higher today

These shares are having a good session on Thursday. But why?

Read more »